

Department of Legislative Services  
Maryland General Assembly  
2015 Session

**FISCAL AND POLICY NOTE**

Senate Bill 337

(Senator Conway)(By Request - Baltimore City  
Administration)

Education, Health, and Environmental Affairs

Health and Government Operations

---

**Public Health - Expedited Partner Therapy Program - Repeal of Termination  
Date**

---

This bill makes permanent the Expedited Partner Therapy (EPT) Program in the Baltimore City Health Department by removing the “pilot” restrictions and the termination date. The bill also repeals the requirement that the Baltimore City Health Department publish annual reports on the operation and performance of the program.

The bill takes effect June 1, 2015.

---

**Fiscal Summary**

**State Effect:** None. The bill primarily affects the Baltimore City Health Department. Existing Department of Health and Mental Hygiene staff can adopt regulations making the program permanent.

**Local Effect:** Expenditures for the Baltimore City Health Department EPT Program (less than \$10,000 annually) are maintained annually beyond fiscal 2015. No effect on revenues.

**Small Business Effect:** None.

---

**Analysis**

**Current Law:** Baltimore City is the only jurisdiction in the State where EPT is used. Chapter 146 of 2007 established the EPT Pilot Program in the Baltimore City Health Department to provide antibiotic therapy to the partner of a patient diagnosed with either chlamydia or gonorrhea, without making a personal physical assessment of the patient’s

partner. Chapter 146 required the Baltimore City Health Department to report to the Governor and the General Assembly annually on the pilot program's operation and performance. Chapter 136 of 2010 extended the termination date for the EPT Pilot Program from June 30, 2010, until June 30, 2015.

A certified nurse practitioner is the only advanced practice nurse with prescriptive authority under Title 8 of the Health Occupations Article. Certified nurse practitioners are authorized to prescribe drugs under regulations adopted by the State Board of Nursing. A nurse practitioner may personally prepare and dispense a starter dosage of any drug the nurse practitioner is authorized to prescribe to a patient if the starter dosage complies with the statutory labeling requirements, there is not a charge for the starter dosage, and the practitioner enters an appropriate record in the patient's medical record. A starter dosage is an amount of drug sufficient to begin therapy for a 72-hour or less duration or prior to obtaining a larger quantity of the drug to complete therapy. The nurse practitioner also must provide the patient with a written prescription, except for starter dosages or samples dispensed without charge.

A supervising physician and physician assistant may enter into a delegation agreement under which the physician may delegate prescribing and administering of controlled dangerous substances, prescription drugs, or medical devices, and the oral, written, or electronic ordering of medications. The agreement must meet specified statutory requirements.

**Background:** The U.S. Centers for Disease Control and Prevention (CDC) identify EPT as a central component to prevent and control sexually transmitted diseases (STDs) in the United States. Initially developed to control syphilis, EPT became heavily recommended for the treatment of gonorrhea and chlamydia. To help state and local STD programs implement EPT programs, CDC collaborated with the Center for Law and the Public's Health at Georgetown and the Johns Hopkins universities to assess the legal framework concerning EPT across all 50 states and other jurisdictions. According to CDC, state law does not preclude the administration of prescription drugs to a patient for use by partners. However, some states are reluctant to support prescriptions issued outside of a physician-patient relationship. EPT programs are permissible in 36 states.

Chlamydia is the most frequently reported bacterial STD in the United States. An estimated 2.9 million Americans are infected with the disease each year. In women, untreated infection can progress to serious reproductive and other health problems, while complications among men are rare. Gonorrhea is likewise a bacterial STD. CDC estimates that 820,000 individuals in the United States get new gonorrheal infections each year. Left untreated, gonorrhea can cause serious and permanent health problems in both women and

men. Gonorrhea and chlamydia rates in Baltimore are much higher than the national average.

In November 2012, CDC issued updated guidance on the use of EPT in the treatment of gonorrhea based on data from the Gonococcal Isolate Surveillance Project, which indicated that the United States may be in the early stages of the development of clinically significant gonococcal resistance to oral antibiotic treatment. Thus, CDC no longer recommends the routine use of orally administered antibiotics for the treatment of certain types of uncomplicated gonorrhea in the United States. Instead, CDC recommends combination therapy involving shots and oral medication. Shots cannot be administered through EPT programs.

The new guidelines advise that every effort should be made to ensure that a patient's partners from the past 60 days are evaluated and treated with the recommended combination medications. However, because that is not always possible, providers can still consider EPT for heterosexual partners of patients diagnosed with gonorrhea who are unlikely to access timely evaluation and treatment. CDC advises that EPT is not routinely recommended for men who have sex with men because of a high risk for coexisting infections in their partners. Further, the new guideline instructions for partners should include a recommendation that the partners receive a test-of-cure approximately one week after finishing their medication and information on where they can receive a test-of-cure.

The Baltimore City Health Department advises that it continues to use oral antibiotics to treat partners through the EPT Pilot Program because the rates of gonococcal resistance in Baltimore are extremely low. The department monitors for the emergence of gonococcal resistance to oral antibiotic treatments. In 2014, the resistance surveillance program did not detect any resistant cases in Baltimore City.

The Baltimore City Health Department reports that, from October 2007 through December 2014, the Druid and Eastern STD Clinics have provided 3,174 partner packs containing medication and instructions for EPT during 2,524 patient encounters. These encounters represented 2,479 confirmed cases of gonorrhea and/or chlamydia. Although policy allows each patient to take up to three packs for partners, most patients only request one pack. The department found that reinfection rates for patients who accepted EPT packs were lower than those who did not.

**Local Fiscal Effect:** Expenditures of \$10,000 or less annually for the Baltimore City Health Department EPT Program are maintained beyond fiscal 2015 to provide antibiotic medication and instructions for the partners of individuals diagnosed with gonorrhea and/or chlamydia and who are in EPT therapy. This estimate assumes that the number of patients

treated through the EPT Program remains steady and that the majority of patients continue to request one partner treatment pack.

**Additional Comments:** Senate Bill 599 of 2015 would expand EPT therapy throughout the State in both public and private health care settings.

---

### **Additional Information**

**Prior Introductions:** None.

**Cross File:** HB 228 (Delegate Anderson)(By Request - Baltimore City Administration) - Health and Government Operations.

**Information Source(s):** Baltimore City, Department of Health and Mental Hygiene, U.S. Centers for Disease Control and Prevention, Maryland Association of County Health Officers, Department of Legislative Services

**Fiscal Note History:** First Reader - February 16, 2015  
md/ljm

---

Analysis by: Kathleen P. Kennedy

Direct Inquiries to:  
(410) 946-5510  
(301) 970-5510